Pacira Pharmaceuticals (PCRX) PT Raised to $63 at RBC Capital
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $26.60 --0%
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 2
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 2
Join SI Premium – FREE
RBC Capital analyst Randall Stanicky raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $63.00 (from $62.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Kepler Cheuvreux Downgrades Ipsos SA (IPS:FP) (IPSOF) to Hold
- Lululemon (LULU) PT Lowered to $106 at UBS
- Chewy Inc. (CHWY) PT Lowered to $32 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
